fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

CE MARK for AVEIR DR, the world’s fist dual chamber leadless pacemaker system – Abbott

Written by | 12 Jun 2024

Abbott announced it has received CE Mark in Europe for the AVEIR dual chamber (DR) leadless pacemaker system, the world’s first dual chamber leadless pacemaker that treats people… read more.

Abbott/Thoratec Corp recalls HeartMate II and HeartMate 3 left ventricular assist system due to long-term buildup causing an obstruction

Written by | 25 Apr 2024

Abbott/Thoratec Corp. is recalling HeartMate II and HeartMate 3 Left Ventricular Assist System (LVAS) due to an issue called Extrinsic Outflow Graft Obstruction, (EOGO) . This happens when… read more.

Abbott recalls HeartMate Touch communication system for unintentional pump start and stop

Written by | 16 Mar 2024

The HeartMate Touch Communication System monitors patients who have an implantable HeartMate 3 Left Ventricular Assist Device. The HeartMate Touch Communication System works with the HeartMate System Controller…. read more.

FDA approval for Liberta RC DBS system to treat movement disorders – Abbott

Written by | 2 Feb 2024

Abbott announced that it received approval from the FDA to launch the Liberta RC DBS system, the world’s smallest rechargeable deep brain stimulation (DBS) device with remote programming,… read more.

Tandem Diabetes Care’s T;SLIM x2 insulin pump is the first automated insulin delivery system to integrate with Abbott’s new FreeStyle Libre 2 Plus sensor

Written by | 22 Jan 2024

Abbott and Tandem Diabetes Care, Inc. a leading insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated… read more.

Late-breaking data showcase the benefits of Abbott’s minimally invasive devices for people with leaky heart valves

Written by | 28 Oct 2023

Abbott announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease . Data include findings from the… read more.

Abbott initiates US market withdrawal of Trifecta family of heart valves

Written by | 10 Aug 2023

Abbott is initiating a US market withdrawal for the Trifecta family of valves and will be removing the limited remaining inventory from the field. On February 27, 2023,… read more.

FDA approval for SurVeil drug-coated balloon for percutaneous transluminal angioplasty – Abbott

Written by | 28 Jun 2023

Surmodics, Inc. announced the receipt of FDA approval for the SurVeil drug-coated balloon (DCB). The SurVeil DCB may now be marketed and sold in the U.S. to physicians… read more.

FDA approves Amplatzer Amulet Device to treat people with atrial fibrillation at risk of stroke – Abbott

Written by | 3 Sep 2021

Abbott has announced that the FDA approved the company’s Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.